
About Metabolon
Metabolon is a Healthcare company based in Morrisville (United States) founded in 2000. Solutions for biomarker discovery and diagnostic testing are provided. Metabolon has raised $165.87 million across 19 funding rounds from investors including Sumitomo Corporation, ARE and East West Bank. Metabolon has completed 2 acquisitions, including Lipomics and Metabolomic Discoveries. Its website metabolon.com draws about 28 thousand monthly visits. Metabolon offers products and services including Bioinformatics Platform, Untargeted Metabolomics, Targeted Metabolomics, and Lipidomics. Its focus areas include Life Sciences, Metabolic Diseases, In Vitro Diagnostic Tests and Inborn Errors of Metabolism. Its competitors include Maze Therapeutics, Alector and Seer; 3 of its 3 listed competitors have raised funding.
Company details
Metabolon was founded in 2000 and is headquartered in Morrisville, United States. Operations focus on the biotechnology sector, where a biochemical profiling platform is utilized to analyze and identify biochemicals for research in pharmaceuticals, biotech, agriculture, cosmetics, and consumer products. Services include Quantose IR for prediabetes assessment and Meta IMD for detecting inborn errors of metabolism. Development of metabolomics-based tests for early detection of obesity-related metabolic diseases is ongoing.
- Total Equity Funding$165.87M (USD)
in 19 rounds
- Latest Funding Round$7.5M (USD), Series H
Dec 2024
- InvestorsSumitomo Corporation
& 14 more
- Investments & AcquisitionsLipomics
& 1 more
Products & Services of Metabolon
Metabolon offers a comprehensive portfolio of products and services, including Bioinformatics Platform, Untargeted Metabolomics, Targeted Metabolomics, and Lipidomics.
Tool for visualizing and analyzing metabolomics data sets
Analysis of wide-ranging metabolites for research
Quantification of specific metabolites for studies
Identification of lipid species in biological samples
Apps and channels of Metabolon
its YouTube channel Metabolon has 810 subscribers and 30 videos.
Videos from Metabolon
The most watched videos on Metabolon's YouTube channel, Metabolon (810 subscribers). Click a video to play it here.
More on Metabolon.
Funding Insights of Metabolon
Metabolon has successfully raised a total of $165.87M across 19 strategic funding rounds. The most recent funding activity was a Series H round of $7.5 million completed in December 2024. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding $165.87M
- Total Rounds 19
- Last Round Series H — $7.5M
- First Round $300,000
(Mar 2003)
- Investors Count 15
Latest 10 of 19 funding rounds of Metabolon with amounts and investors; the two latest post-money valuations are shown, the rest are part of the premium plan.
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Dec 2024 | $7.5M | Series H | – | – | – |
| May 2024 | $298,264 | Grant | – | – | |
| Sep 2023 | $297,666 | Grant | – | – | |
| Nov 2022 | $25M | Series H | – | – | – |
| Sep 2020 | $21.77M | Series G | – | – | – |
| Mar 2020 | $7.75M | Series F | – | – | – |
| Oct 2018 | $30M | Debt – Conventional | – | – | |
| Aug 2018 | $7.3M | Series F | – | – | – |
| Dec 2016 | $15M | Series F | – | EW Healthcare Partners | – |
| Aug 2016 | $15M | Series F | – | EW Healthcare Partners | – |
15 investors in total: 15 institutional.
Investors in Metabolon
Metabolon has secured backing from 15 investors, including institutional and venture fund investors. Prominent investors backing the company include Sumitomo Corporation, ARE and East West Bank.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
Diversified debt funding is provided for growth capital opportunities. | innovatuscp.com | New York, United States | ||
Growth-stage healthcare companies are invested in by EW Healthcare Partners. | ewhealthcare.com | New York, United States | ||
Growth equity investments are made in lower middle market companies. | 1995 | camdenpartners.com | Owings Mills, United States | |
| aurorafunds.com | ||||
Early-stage life-sciences investments are targeted in Europe and the US. | syngentaventures.com | Basel, Switzerland | ||
VC firm funding companies in the US | 1981 | 180degreecapital.com | Montclair, United States | |
Early-stage US investments in technology and offline sectors are targeted. | srfunds.com | Dallas, United States | ||
| trelys.com | ||||
Public health and human services are overseen by HHS. | 1953 | hhs.gov | ||
Commercial banking services are offered to individuals and businesses. | 1973 | eastwestbank.com | Los Angeles, United States |
Investor details for Metabolon
The complete investor list, round-by-round participation and investor portfolios require an active premium plan.
- Complete investor list
- Round participation
- Investor portfolios
- Co-investor network
Verified entity values are shown only after access is granted.
People of Metabolon
62 people are tracked at Metabolon (27 in leadership, 6 in board & advisors, 29 in team).
| Name | Role | Group |
|---|---|---|
Sean Iverson | VP, Global Marketing | Leadership |
Charles Wayland | VP, Global Head of Sales | Leadership |
Leane Woody | Director Laboratory Operations | Leadership |
Gerald M. Haines II | CFO | Leadership |
Karl Bradshaw | Chief Business Officer | Leadership |
Rohan F. Hastie | President, Director & CEO | Leadership |
Tom Houseman | VP, Operations | Leadership |
Kari Wong | Scientific Strategy Director | Leadership |
Annie Evans | Sr. Director Research And Development | Leadership |
Edward Karoly | Senior Director, Discovery & Translational Sciences | Leadership |
Jim Fuller | Clinical Laboratory Director | Leadership |
Kay Lawton | Vice President | Leadership |
Dr. Patrick Arnott | Sales & Business Development Director | Leadership |
Heino M Heyman | Director: Global Field Metabolomics Sciences | Leadership |
Janice Jones | Director, Discovery & Development | Leadership |
Tim Delany | Corporate Development Director | Leadership |
Dr. Nina Görner | Business Development Director | Leadership |
Zoltan Bognar | Sales And Business Development Director, DACH | Leadership |
Julián Palacios Abril | Sales And Business Development Director Southern Europe & ROW | Leadership |
Lindsay Baskervill | Associate Director, Global Sales Operations | Leadership |
42 more people are available in the full profile.
Complete people profiles for Metabolon
Full employee and board profiles, team structure, tenure and professional contact details require an active premium plan.
- Full employee list
- Team structure
- Board tenure
- Professional contacts
Verified entity values are shown only after access is granted.
Investments & Acquisitions by Metabolon
Metabolon has strategically engaged in corporate development activities, having acquired 2 companies. Notable acquisitions include Lipomics and Metabolomic Discoveries.
| Company Name | Description | Domain | Location | Founded | Acquired | Amount |
|---|---|---|---|---|---|---|
Metabolomic data analysis software and services are provided for research. | metabolomicdiscoveries.com | Potsdam, Germany | 2009 | Sep 2017 | •••• | |
Diagnostics for metabolic, cardiovascular, and inflammatory conditions are developed. | lipomics.com | Sacramento, United States | 2000 | Aug 2012 | •••• |
Complete acquisition details for Metabolon
Acquired stakes, deal sources and the complete acquisition history require an active premium plan.
- Acquired stakes
- Deal sources
- Complete history
- Exports
Verified entity values are shown only after access is granted.
Timeline of Metabolon
5 dated milestones of Metabolon across 24 years, from founding to its latest funding, stage changes and deals.
- Founded Metabolon is founded.
- Funding First funding round of $300K.
- Acquisition Acquires Lipomics.
- Acquisition Acquires Metabolomic Discoveries.
- Funding Latest funding round, Series H, of $7.5M.
Competitors of Metabolon
Metabolon has 3 listed competitors in our database, 3 of them funded. They include Maze Therapeutics, Alector and Seer.
| Company Name | Domain | Founded | HQ Location | Total funding | Employees | Description |
|---|---|---|---|---|---|---|
| mazetx.com | 2018 | Redwood, United States | $496M | 111 | Genetic biomarkers are developed for neurological, metabolic, and renal diseases. | |
| alector.com | 2013 | San Francisco, United States | $214.78M | 211 | Immuno-modulatory therapies for dementia and neurodegenerative disorders are developed. | |
| seer.bio | 2017 | San Francisco, United States | $127.5M | 89 | Proteomics platform developed for early cancer and neurological disease detection. |
Detailed competitors of Metabolon
The full competitor set, operating metrics and side-by-side benchmarks require an active premium plan.
- Full competitor set
- Operating metrics
- Benchmarks
- Competitive positioning
Verified entity values are shown only after access is granted.
Web traffic of Metabolon
The website of Metabolon (metabolon.com) receives about 28.2K visits a month.
- Monthly visits28.2K
▲ 4.2% vs previous month
Websites whose visitors overlap most with Metabolon. Affinity shows how closely the audiences match.
| Website | Domain | Audience affinity | Monthly visits | Global rank | Profile |
|---|---|---|---|---|---|
biocarta.com | biocarta.com | 100% | – | ||
metabolomics.bbsrc.ac.uk | metabolomics.bbsrc.ac.uk | 99% | – | ||
ecocyc.org | ecocyc.org | 99% | #805,843 | – | |
web.expasy.org | web.expasy.org | 83% | – | ||
metabolomicsworkbench.org | metabolomicsworkbench.org | 83% | #671,682 | – | |
| •••••••••• | ••••••.com | ••% | •.•M | #••••• | – |
| •••••••••• | ••••••.com | ••% | •.•M | #••••• | – |
| •••••••••• | ••••••.com | ••% | •.•M | #••••• | – |
All 29 similar websites and full traffic analytics for Metabolon
The complete similar-websites list, audience overlap and engagement analytics require an active premium plan.
- 29 similar websites
- Audience overlap
- Engagement analytics
- Traffic by brand
Verified entity values are shown only after access is granted.
Top companies in Metabolic Diseases
3 companies that operate in the same segment as Metabolon (Metabolic Diseases) in United States, ranked by their profile score on The Company Check.
| Company | Description | Founded | Location | Total funding | Revenue | Employees |
|---|---|---|---|---|---|---|
Satiety induction through digestable gastric balloon introduced via a swallowed capsule | 2009 | Wellesley, Massachusetts, United States | USD 174.04 M | USD 32.11 M | 137 | |
Developer of peptide therapeutics for the treatment of rare genetic deficiencies | 2010 | Boston, Massachusetts, United States | USD 84 M | USD 189.76 M | 283 | |
Developer of small-molecule drugs | 1991 | Los Angeles, California, United States | USD 50 M | USD 348.97 M | 407 |
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Related news about Metabolon
Complete news archive for Metabolon
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Metabolon
Metabolon was founded in 2000 and raised its 1st funding round 3 years after it was founded.
Metabolon is headquartered in Morrisville, United States.
Metabolon is a funded company, having raised a total of $165.87M across 19 funding rounds to date. The company's 1st funding round was a Series F of $15M, raised on Mar 2003.
Metabolon was founded in 2000 and is headquartered in Morrisville, United States. Operations focus on the biotechnology sector, where a biochemical profiling platform is utilized to analyze and identify biochemicals for research in pharmaceuticals, biotech, agriculture, cosmetics, and consumer products. Services include Quantose IR for prediabetes assessment and Meta IMD for detecting inborn errors of metabolism. Development of metabolomics-based tests for early detection of obesity-related metabolic diseases is ongoing.
Metabolon's top competitors include Alector, Maze Therapeutics and Seer.
Metabolon offers Bioinformatics Platform, Untargeted Metabolomics, Targeted Metabolomics, and Lipidomics.
Metabolon has made 2 acquisitions, including Lipomics, and Metabolomic Discoveries.
Metabolon has 15 investors. Key investors include Sumitomo Corporation, ARE, East West Bank, HHS, and Fletcher Spaght.
